IGFBP2 Antibody (1F6F6): sc-130070

IGFBP2 Antibody (1F6F6) is a mouse monoclonal IgG1 antibody that detects Insulin-like growth factor-binding protein 2 (IGFBP2) in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). IGFBP2 plays a crucial role in regulating insulin-like growth factors (IGFs) by acting as a chaperone that escorts IGFs to target tissues, thereby influencing bioavailability and activity. IGFBP2 is predominantly expressed in several human tissues, including fetal eye and fetal brain, highlighting IGFBP2′s importance during development. IGFBP2′s ability to modulate IGF signaling is vital for various physiological processes, including growth and metabolism, and IGFBP2 dysregulation has been implicated in conditions such as cancer and metabolic disorders. IGFBP2′s interaction with IGFs not only affects distribution but also half-life, making IGFBP2 a key player in IGF signaling pathway. Anti-IGFBP2 antibody (1F6F6) serves as an essential tool for researchers exploring IGFBP2′s intricate roles in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGFBP2 Antibody (1F6F6) References:

1. IGFBP2: integrative hub of developmental and oncogenic signaling network.  |  Li, T., et al. 2020. Oncogene. 39: 2243-2257. PMID: 31925333
2. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.  |  Wen, Z., et al. 2023. Cancer Commun (Lond). 43: 562-581. PMID: 37031362
3. METTL3-mediated HOTAIRM1 promotes vasculogenic mimicry icontributionsn glioma via regulating IGFBP2 expression.  |  Wu, Z. and Wei, N. 2023. J Transl Med. 21: 855. PMID: 38012763
4. IGFBP2 levels associated with Alzheimer disease.  |  Kiani, L. 2024. Nat Rev Neurol. 20: 1. PMID: 38049639
5. A human omentum-specific mesothelial-like stromal population inhibits adipogenesis through IGFBP2 secretion.  |  Ferrero, R., et al. 2024. Cell Metab. 36: 1566-1585.e9. PMID: 38729152
6. Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.  |  Xu, W., et al. 2024. J Exp Clin Cancer Res. 43: 149. PMID: 38778379
7. IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease.  |  Wang, X., et al. 2024. Apoptosis. 29: 1109-1125. PMID: 38796567
8. IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.  |  Lu, H., et al. 2024. Cell Death Dis. 15: 447. PMID: 38918360
9. A spatiotemporal molecular atlas of mouse spinal cord injury identifies a distinct astrocyte subpopulation and therapeutic potential of IGFBP2.  |  Wang, Z., et al. 2024. Dev Cell. 59: 2787-2803.e8. PMID: 39029468
10. IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway.  |  Zhai, T., et al. 2024. Mol Metab. 89: 102026. PMID: 39299533

The preferred IGFBP2 antibody is IGFBP2 Antibody (C-10): sc-25285.